Vancomycin: does it still have a role as an antistaphylococcal agent?

References

• Elting LS, Rubenstein EB, Kurtin D et al. Mississippi mud in the 1990s: risks and outcomes of vancomycin-associated toxicity in general oncology practice. Cancer83, 2597–2607 (1998).
   PubMed Web of Science ®Google Scholar
• Chambers HF. The changing epidemiology of Staphylococcus aureus.Emerg. Infect. Dis.7, 178–182 (2001).
   PubMed Web of Science ®Google Scholar
• Jevons MP. “Celbenin”-resistant staphylococci. Br. Med. J.1, 124–125 (1961).
   Web of Science ®Google Scholar
• Uttley AH, Collins CH, Naidoo J, George RC. Vancomycin-resistant enterococci. Lancet1, 57–58 (1988).
   PubMed Web of Science ®Google Scholar
• Small PM, Chambers HF. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob. Agents Chemother.34, 1227–1231 (1990).
   PubMed Web of Science ®Google Scholar
• Appelbaum PC. MRSA – the tip of the iceberg. Clin. Microbiol. Infect.12(Suppl. 2), 3–10 (2006).
   PubMed Web of Science ®Google Scholar
• Wang G, Hindler JF, Ward KW, Bruckner DA. Increased vancomycin minimal inhibitory concentrations in Staphylococcus aureus clinical isolates from a university hospital during a five-year period. J. Clin. Microbiol.44(11), 3883–3886 (2006).
   PubMed Web of Science ®Google Scholar
• Kapadia M, Coyle E, Prince R et al. Declining in vitro activity of vancomycin against Staphylococcus aureus isolates from cancer patients. Presented at: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, USA, December 16–19, 2005 (Abstract E-807).
   Google Scholar
• Golan Y, Baiez-Giangreco C, O’Sullivan C, Snydman DR. Trends in vancomycin susceptibility among consecutive MRSA bacteremia isolates. Presented at: 44th Annual Meeting of the Infectious Disease Society of America, October 12–15, Toronto, Canada, 2006, Abstract LB-11.
   Google Scholar
• Huang V, Tenover FC, McGowan JE Jr. Detecting Staphylococcus aureus isolates with reduced vancomycin susceptibility. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 27–30, CA, USA, 2006 (Abstract D-811).
   Google Scholar
• LaPlante KL, Rybak MJ. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob. Agents Chemother.48, 4665–4672 (2004).
   PubMed Web of Science ®Google Scholar
• Ekdahl C, Hanberger H, Hallgren A et al. Rapid decrease of free vancomycin in dense staphylococcal cultures. Eur. J. Clin. Microbiol. Infect. Dis.24, 596–602 (2005).
   PubMed Web of Science ®Google Scholar
• Liu C, Chambers HF. Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods. Antimicrob. Agents Chemother.47, 3040–3045 (2003).
   PubMed Web of Science ®Google Scholar
• Hussain FM, Boyle-Vavra S, Shete PB, Daum RS. Evidence for a continuum of decreased vancomycin susceptibility in unselected Staphylococcus aureus clinical isolates. J. Infect. Dis.186, 661–667 (2002).
   PubMed Web of Science ®Google Scholar
• Howden BP, Johnson PD, Ward PB et al. Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob. Agents Chemother.50, 3039–3047 (2006).
   PubMed Web of Science ®Google Scholar
• Charles PG, Ward PB, Johnson PD et al. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus.Clin. Infect. Dis.38, 448–451 (2004).
   PubMed Web of Science ®Google Scholar
• Fernández Guerrero ML, de Górgolas M. Comparative activity of cloxacillin and vancomycin against methicillin-susceptible Staphylococcus aureus experimental endocarditis. J. Antimicrob. Chemother.58(5), 1066–1069 (2006).
   PubMed Web of Science ®Google Scholar
• Gunderson BW, Ibrahim KH, Peloquin CA et al. Comparison of linezolid activities under aerobic and anaerobic conditions against methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus faecium.Antimicrob. Agents Chemother.47, 398–399 (2003).
   PubMed Web of Science ®Google Scholar
• Lamp KC, Rybak MJ, Bailey EM, Kaatz GW. In vitro pharmacodynamic effects of concentration, pH, and growth phase on serum bactericidal activities of daptomycin and vancomycin. Antimicrob. Agents Chemother.36, 2709–2714 (1992).
   PubMed Web of Science ®Google Scholar
• Larsson AJ, Walker KJ, Raddatz JK, Rotschafer JC. The concentration-independent effect of monoexponential and biexponential decay in vancomycin concentrations on the killing of Staphylococcus aureus under aerobic and anaerobic conditions. J. Antimicrob. Chemother.38, 589–597 (1996).
   PubMed Web of Science ®Google Scholar
• Saginur R, Stdenis M, Ferris W, Aaron SD, Chan F, Lee C, Ramotar K. Multiple combination bactericidal testing of staphylococcal biofilms from implant-associated infections. Antimicrob. Agents Chemother.50, 55–61 (2006).
   PubMed Web of Science ®Google Scholar
• Wiederhold NP, Coyle EA, Raad II, Prince RA, Lewis RE. Antibacterial activity of linezolid and vancomycin in an in vitro pharmacodynamic model of Gram-positive catheter-related bacteremia. J. Antimicrob. Chemother.55, 792–795 (2005).
   PubMed Web of Science ®Google Scholar
• Mathur T, Singhal S, Khan S, Upadhyay D, Fatma T, Rattan A. Adverse effect of staphylococci slime on in vitro activity of glycopeptides. Jpn J. Infect. Dis.58, 353–357 (2005).
   PubMed Web of Science ®Google Scholar
• May J, Shannon K, King A, French G. Glycopeptide tolerance in Staphylococcus aureus.J. Antimicrob. Chemother.42, 189–192 (1998).
   PubMed Web of Science ®Google Scholar
• Safdar A, Rolston KV. Vancomycin tolerance, a potential mechanism for refractory Gram-positive bacteremia observational study in patients with cancer. Cancer106, 1815–1820 (2006).
   PubMed Web of Science ®Google Scholar
• Sakoulas G, Moise-Broder PA, Schentag J et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J. Clin. Microbiol.42, 2398–2340 (2004).
   PubMed Web of Science ®Google Scholar
• Sieradzki K, Tomasz A. Inhibition of the autolytic system by vancomycin causes mimicry of vancomycin-intermediate Staphylococcus aureus-type resistance, cell concentration dependence of the MIC, and antibiotic tolerance in vancomycin-susceptible S. aureus.Antimicrob. Agents Chemother.50, 527–533 (2006).
   PubMed Web of Science ®Google Scholar
• Sakoulas G, Alder J, Thauvin-Eliopoulos C et al. Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob. Agents Chemother.50, 1581–1585 (2006).
   PubMed Web of Science ®Google Scholar
• Cui L, Tominaga E, Neoh HM, Hiramatsu K. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus.Antimicrob. Agents Chemother.50, 1079–1082 (2006).
   PubMed Web of Science ®Google Scholar
• Ackerman BH, Taylor EH, Olsen KM et al. Vancomycin serum protein binding determination by ultrafiltration.Drug Intell. Clin. Pharm.22, 300–303 (1988)
   PubMedGoogle Scholar
• Sun H, Maderazo EG, Krusell AR. Serum protein-binding characteristics of vancomycin. Antimicrob. Agents Chemother.37, 1132–1136 (1993).
   PubMed Web of Science ®Google Scholar
• Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin. Infect. Dis.42, S35–S39 (2006).
   PubMed Web of Science ®Google Scholar
• Skhirtladze K, Hutschala D, Fleck T et al. Impaired target site penetration of vancomycin in diabetic patients following cardiac surgery. Antimicrob. Agents Chemother.50, 1372–1375 (2006).
   PubMed Web of Science ®Google Scholar
• Lamer C, de Beco V, Soler P et al. Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients. Antimicrob. Agents Chemother.46, 1475–1480 (2002).
   PubMed Web of Science ®Google Scholar
• Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections.Clin. Pharmacokinet.43, 925–942 (2004).
   PubMed Web of Science ®Google Scholar
• Craig WA, Andes DR. In vivo pharmacodynamics of vancomycin against VISA, heteroresistant VISA and VSSA in the neutropenic murine thigh-infection model. Presented at: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 27–30, CA, USA, 2006 (Abstract A-644).
   Google Scholar
• American Thoracic Society. Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am. J. Resp. Crit. Care Med.171, 388–416 (2005).
   PubMed Web of Science ®Google Scholar
• Jeffres MN, Isakow W, Doherty JA et al. Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia. Chest130, 947–955 (2006).
   PubMed Web of Science ®Google Scholar
• Hidayat L, Hsu D, Shriner K, Wong-Beringer A. Outcomes of vancomycin-treated methicillin-resistant Staphylococcus aureus infections targeting higher trough concentration. Presented at: 43rd Annual Meeting of the Infectious Disease Society of America, October 6–9, CA, USA, 2005 (Abstract 352).
   Google Scholar
• Bernard L, Vaudaux P, Vuagnat A et al. Effect of vancomycin therapy for osteomyelitis on colonization by methicillin-resistant Staphylococcus aureus: lack of emergence of glycopeptide resistance. Infect. Control Hosp. Epidemiol.24, 650–654 (2003).
   PubMed Web of Science ®Google Scholar
• Lee-Such SC, Overholser BR, Munoz-Price LS. Nephrotoxicity associated with aggressive vancomycin therapy. 46th ICAAC. September 27–30, CA, USA, 2006, Abstract L-1298.
   Google Scholar
• Jeffres MN, Micek ST, Isakow W et al. Increased incidence of nephrotoxicity with higher vancomycin serum trough concentrations. Presented at: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 27–30, CA, USA, 2006 (Abstract K-789).
   Google Scholar
• McKinnon PS, Lodise TP Jr, Tybak MJ. Impact of initial treatment with vancomycin versus a β-lactam and costs of methicillin-susceptible Staphylococcus aureus bacteremia. Presented at: 40th Annual Meeting of the Infectious Disease Society of America. October 24–27, IL, USA, 2002 (Abstract 579).
   Google Scholar
• Chang FY, Peacock JE Jr, Musher DM et al. Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study. Medicine82, 333–339 (2003).
   PubMed Web of Science ®Google Scholar
• Stryjewski ME, Chu VH, O’Riordan WD et al. Televancin versus standard therapy for treatment of complicated skin and soft tissue infections caused by Gram-positive bacteria: FAST 2 study.Antimicrob. Agents Chemother.50, 862–867 (2006).
   PubMed Web of Science ®Google Scholar
• Corey R. ATLAS: televancin in cSSSI, a landmark trial for MRSA. Presented at: 3rd International Symposium on Resistant Gram-Positive Infections. Ontario, Canada, October 9–11, 2006.
   Google Scholar
• Weigelt J, Itani K, Stevens D et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob. Agents Chemother.49, 2260–2266 (2005).
   PubMed Web of Science ®Google Scholar
• Sharpe JN, Shively EH, Polk HC Jr. Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus.Am. J. Surg.189, 425–428 (2005).
   PubMed Web of Science ®Google Scholar
• Weigelt J, Kaafarani HM, Itani KM, Swanson RN. Linezolid eradicates MRSA better than vancomycin from surgical-site infections. Am. J. Surg.188, 760–766 (2004).
   PubMed Web of Science ®Google Scholar
• Goldstein BP, Seltzer E, Flamm R, Sahm D. Dalbavancin phase 3 skin and skin structure studies: pathogens and microbiological efficacy. Presented at: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC, December 16–19, 2005 (Abstract L-1577).
   Google Scholar
• Wunderink RG, Rello J, Cammarata SK et al. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest124, 1789–1797 (2003).
   PubMed Web of Science ®Google Scholar
• Kollef MH, Rello J, Cammarata SK et al. Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Med.30, 388–394 (2004).
   PubMed Web of Science ®Google Scholar
• Levine DP, Fromm BS, Reddy BR. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann. Intern. Med.115, 674–680 (1991).
   PubMed Web of Science ®Google Scholar
• Cosgrove S, Fowler V, Boucher H et al. Initial low-dose gentamicin in the treatment of S. aureus bacteremia and endocarditis is nephrotoxic. Presented at: 44th Annual Meeting of the Infectious Disease Society of America. October 12–15, Toronto, Canada, 2006 (Abstract 371).
   Google Scholar
• Jones RN. Microbiological features of vancomycin in the 21st Century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains.Clin. Infect. Dis.42, S14–S24 (2006).
   PubMed Web of Science ®Google Scholar
• Eguia JM, Liu C, Moore M et al. Low colonization prevalence of Staphylococcus aureus with reduced vancomycin susceptibility among patients undergoing hemodialysis in the San Francisco Bay area. Clin. Infect. Dis.40, 1617–1624 (2005).
   PubMed Web of Science ®Google Scholar
• Kleinschmidt SL, Munckhof WJ, Nimmo GR. In vitro exposure of community-associated methicillin-resistant Staphylococcus aureus (MRSA) strains to vancomycin: does vancomycin resistance occur? Int. J. Antimicrob. Agents27, 168–170 (2006).
   PubMed Web of Science ®Google Scholar
• Pfeltz RF, Singh VK, Schmidt JL et al. Characterization of passage-selected vancomycin-resistant Staphylococcus aureus strains of diverse parental backgrounds. Antimicrob. Agents Chemother.44, 294–303 (2000).
   PubMed Web of Science ®Google Scholar
• McCallum N, Karauzum H, Getzmann R et al. In vivo survival of teicoplanin-resistant Staphylococcus aureus and fitness cost of teicoplanin resistance. Antimicrob. Agents Chemother.50, 2352–2360 (2006).
   PubMed Web of Science ®Google Scholar
• Lee S, Cho Y, Kwon H et al. Biological effect of vancomycin resistance in Staphylococus aureus. Presented at: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. September 27–30, CA, USA, 2006 (Abstract C1–1826).
   Google Scholar
• Finberg RW, Moellering RC, Tally FP et al. The importance of bactericidal drugs: future direction in infectious disease. Clin. Infect. Dis.39, 1314–1320 (2004).
   PubMed Web of Science ®Google Scholar
• Pankey GA, Sabath LD. Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of Gram-positive infections. Clin. Infect. Dis.38, 864–870 (2004).
   PubMed Web of Science ®Google Scholar
• Tattevin P, Camus C. What can we learn from studies comparing linezolid with vancomycin in neutropenic patients when vancomycin dosages are not optimized? Clin. Infect. Dis.42, 1813–1814 (2006).
   PubMed Web of Science ®Google Scholar
• Shorr AF, Kunkel MJ, Kollef M. Linezolid versus vancomycin for Staphylococcus aureus bacteremia: pooled analysis of randomized studies. J. Antimicrob. Chemother.56, 923–929 (2005).
   PubMed Web of Science ®Google Scholar
• Powers JH, Ross DB, Soreth J. Linezolid and vancomycin for methicillin-resistant Staphylococcus aureus nosocomial pneumonia: the subtleties of subgroup analyses. Chest126, 314–315 (2004).
   PubMed Web of Science ®Google Scholar
• Fowler VG, Boucher HW, Corey R et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus.N. Engl. J. Med.355, 653–665 (2006).
   PubMed Web of Science ®Google Scholar
• Noel GJ, Strauss RS, Pypstra R; 00154 Study Group. Successful treatment of complicated skin infections due to staphylococci, including methicillin-resistant Staphylococcus aureus with ceftibiprole. Presented at: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. September 27–30, CA, USA, 2006 (Abstract L-1212).
   Google Scholar
• Ellis-Grosse EJ, Babinchak T, Dartois N et al. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind comparison studies with vancomycin–aztreonam. Clin. Infect. Dis.41, S341–S353 (2005).
   PubMed Web of Science ®Google Scholar
• Arbeit RD, Maki D, Tally FP et al. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin. Infect. Dis.38, 1673–1681 (2004).
   PubMed Web of Science ®Google Scholar
• Deresinski S. Methicillin-resistant Staphylococcus aureus: an evolutionary, epidemiologic, and therapeutic odyssey.Clin. Infect. Dis.40, 562–573 (2005).
   PubMed Web of Science ®Google Scholar
• Deresinski S. Antistaphylococcal vaccines and immunoglobulins: current status and future prospects. Drugs66, 1797–806 (2006).
   PubMed Web of Science ®Google Scholar